The pathogenesis of lupus nephritis

Journal of the American Society of Nephrology

Volumn 24, Issue 9, 2013, Pages 1357-1366

  Lech, Maciej ^a   Anders, Hans Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; ATACICEPT; AUTOANTIGEN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; BORTEZOMIB; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR; CYCLOPHOSPHAMIDE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; EPRATUZUMAB; HYDROXYCHLOROQUINE; MNOX E36; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEIC ACID; RITUXIMAB; SIFALIMUMAB; STEROID; TABALUMAB; TOCILIZUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DENDRITIC CELL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; GENETIC VARIABILITY; HELPER CELL; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INFECTION; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE REPAIR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS PARTICLE;

EID: 84884321720     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013010026     Document Type: Review

References (108)

1. Liu Z, Davidson A: Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 18: 871-882, 2012
2. Tsokos GC: Systemic lupus erythematosus. N Engl JMed 365: 2110-2121, 2011
3. Goodnow CC: Multistep pathogenesis of autoimmune disease. Cell 130: 25-35, 2007
4. Saxena R, Mahajan T, Mohan C: Lupus nephritis: Current update. Arthritis Res Ther 13: 240, 2011
5. Migliorini A, Anders HJ: A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 8: 183-189, 2012
6. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M: The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6: 280-289, 2010
7. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 107: 9813-9818, 2010
8. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ: Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 187: 538-552, 2011
9. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V: Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3: 73ra20, 2011
10. Lande R, Ganguly D, Facchinetti V, Frasca L, ConradC, Gregorio J,Meller S,ChamilosG, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M: Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 3: 73ra19, 2011
11. Bosch X: Systemic lupus erythematosus and the neutrophil.N Engl J Med 365: 758-760, 2011
12. Hof D, Raats JM, Pruijn GJ: Apoptotic modifications affect the autoreactivity of the U1 snRNP autoantigen. Autoimmun Rev 4: 380-388, 2005
13. Huck S, Deveaud E, Namane A, Zouali M: Abnormal DNA methylation and deoxycytosinedeoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J 13: 1415-1422, 1999
14. Karikó K, Ni H, Capodici J, Lamphier M, Weissman D: mRNA is an endogenous ligand for Toll-like receptor. J Biol Chem 279: 12542-12550, 2004
15. Savarese E, Chae OW, Trowitzsch S,Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A: U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107: 3229-3234, 2006
16. Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ, Krug A: Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and developmentof murine lupus nephritis. ArthritisRheum 58: 1107-1115, 2008
17. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A: RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202: 1171-1177, 2005
18. Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ: Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 205: 1879-1888, 2008
19. Lech M, Skuginna V, Kulkarni OP, Gong J, Wei T, Stark RW, Garlanda C, Mantovani A, Anders HJ: Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol 220: 596-607, 2010
20. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607, 2002
21. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, PunaroM, Bolland S, SoumelisV, Banchereau J, Coffman RL, Pascual V, Barrat FJ: TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941, 2010
22. Patole PS, Zecher D, Pawar RD, Gröne HJ, Schlöndorff D, Anders HJ: G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 16: 3273-3280, 2005
23. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ: Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 18: 1721-1731, 2007
24. Teichmann LL,OlsML, KashgarianM, Reizis B, Kaplan DH, ShlomchikMJ:Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 33: 967-978, 2010
25. Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336, 2005
26. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells inmurine lupus. J ExpMed 189: 1639-1648, 1999
27. Zikherman J, Parameswaran R, Weiss A: Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489: 160-164, 2012
28. Allam R, Sayyed SG, Kulkarni O, Lichtnekert J, Anders HJ: Murine double minute-2 drives systemic lupus erythematosus and lupus nephritis. J Am Soc Nephrol 22: 2016-2027, 2011
29. Liu Z, Davidson A: BAFF and selection of autoreactive B cells. Trends Immunol 32: 388-394, 2011
30. Gayed M, Gordon C: Novel treatments for systemic lupus erythematosus. Curr Opin Investig Drugs 11: 1256-1264, 2010
31. Lech M, Weidenbusch M, Kulkarni OP, Ryu M, Darisipudi MN, Susanti HE, Mittruecker HW, Mak TW, Anders HJ: IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J AmSoc Nephrol 22: 1443-1452, 2011
32. Caricchio R, McPhie L, Cohen PL: Ultraviolet B radiation-induced cell death: Critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 171: 5778-5786, 2003
33. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B: Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140: 2197-2200, 1988
34. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33: 1665-1673, 1990
35. Hughes GC: Progesterone and autoimmune disease. Autoimmun Rev 11: A502-A514, 2012
36. Tojo T, Friou GJ: Lupus nephritis: Varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 161: 904-906, 1968
37. Jacob N, Stohl W: Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future. Autoimmunity 43: 84-97, 2010
38. Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK,Qu Z,ChenMH,Gao JJ, Li ZY, Zheng X, Ao J, Zhu SN, Wang SX, Zhao MH, ZouWZ, Liu G: Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 77: 820-829, 2010
39. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International Society of Nephrology Working GroupontheClassification of LupusNephritis Renal Pathology Society Working Group on the Classification of Lupus Nephritis: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530, 2004
40. Nowling TK, Gilkeson GS: Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 13: 250, 2011
41. Yung S, Chan TM: Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: Getting to know the unknown. Clin Dev Immunol 2012: 139365, 2012
42. Mortensen ES, Rekvig OP: Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20: 696-704, 2009
43. Hedberg A, Fismen S, Fenton KA, Fenton C, Osterud B, Mortensen ES, Rekvig OP: Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 63: 1065-1075, 2011
44. Yung S, Cheung KF, Zhang Q, Chan TM: Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 21: 1912-1927, 2010
45. Zhao Z, Deocharan B, Scherer PE, Ozelius LJ, Putterman C: Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: The role of alpha-actinin. J Immunol 176: 7704-7714, 2006
46. Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA: Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 44: 373-383, 2011
47. Fenton KA, Tømmerås B,Marion TN, Rekvig OP: Pure anti-dsDNAmAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 43: 179-188, 2010
48. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S: The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 49: 317-323, 2011
49. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S: The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63: 1076-1085, 2011
50. Bao L, Haas M, Quigg RJ: Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 22: 285-295, 2011
51. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG: FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci 1183: 69-88, 2010
52. Allam R, Lichtnekert J, Moll A, Taubitz A, Vielhauer V, Anders HJ: Viral RNA and DNA trigger common antiviral responses in mesangial cells. J Am Soc Nephrol 20: 1986-1996, 2009
53. Fluer K, Allam R, Zecher D, Kulkarni O, Lichtnekert J, Schwarz M, Beutler B, Vielhauer V, Anders HJ: Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation- associated gene-5: Implications for viral infection-associated glomerulonephritis. Am J Pathol 175: 2014-2022, 2009
54. Hägele H, Allam R, Pawar RD, Anders HJ: Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. NephrolDialTransplant24: 3312-3318, 2009
55. Hägele H, Allam R, Pawar RD, Reichel CA, Krombach F, Anders HJ: Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway. AmJ Pathol 175: 1896-1904, 2009
56. Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C: Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 183: 6831-6838, 2009
57. Anders HJ, Lichtnekert J, Allam R: Interferonalpha and-beta in kidney inflammation. Kidney Int 77: 848-854, 2010
58. Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB: Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A 107: 3012-3017, 2010
59. Anders HJ, Vielhauer V, Eis V, Linde Y, KretzlerM, Perez de LemaG, Strutz F, Bauer S, RutzM,WagnerH,GröneHJ, Schlöndorff D: Activation of toll-like receptor-9 induces progression of renal disease inMRL-Fas(lpr) mice. FASEB J 18: 534-536, 2004
60. Rich SA: Human lupus inclusions and interferon. Science 213: 772-775, 1981
61. Allam R, Anders HJ: The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 20: 538-544, 2008
62. Wang Y, Ito S, Chino Y, Goto D,Matsumoto I, Murata H, Tsutsumi A, Hayashi T, Uchida K, Usui J, Yamagata K, Sumida T: Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol 159: 1-10, 2010
63. KulkarniO, AndersHJ: Chemokines in lupus nephritis. Front Biosci 13: 3312-3320, 2008
64. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, Anders HJ: Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18: 2350-2358, 2007
65. Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B: Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 16: 3592-3601, 2005
66. Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D: Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 15: 1504-1513, 2004
67. Chong BF, Mohan C: Targeting the CXCR4/ CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 13: 1147-1153, 2009
68. Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G: The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 170: 1466-1472, 2003
69. Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, Cuccovillo I, Bastone A, Gobbi M, Valentino S, Doni A, Garlanda C, Danese S, Salvatori G, Sassano M, EvangelistaV, RossiB, Zenaro E, Constantin G, Laudanna C, Bottazzi B, Mantovani A: Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 11: 328-334, 2010
70. Lech M, Römmele C, Kulkarni OP, Susanti HE, Migliorini A, Garlanda C, Mantovani A, Anders HJ: Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS ONE 6: e20118, 2011
71. Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM, Quigg RJ, Meffre E, Clark MR: In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 186: 1849-1860, 2011
72. NeusserMA, LindenmeyerMT, Edenhofer I, Gaiser S, Kretzler M, Regele H, Segerer S, Cohen CD: Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24: 98-107, 2011
73. Espeli M, Bökers S, Giannico G, Dickinson HA, Bardsley V, Fogo AB, Smith KG: Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 22: 296-305, 2011
74. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S,Goldman BI, Kehry M, Anolik JH: Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 62: 2443-2457, 2010
75. Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A: Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410mice. Arthritis Rheum 62: 1457-1468, 2010
76. Apostolidis SA, Crispín JC, Tsokos GC: IL-17-producing T cells in lupus nephritis. Lupus 20: 120-124, 2011
77. Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, KretzlerM, Davidson A: A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 186: 4994-5003, 2011
78. Katsiari CG, Liossis SN, Sfikakis PP: The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: A reappraisal. Semin Arthritis Rheum 39: 491-503, 2010
79. Smeets B, Kuppe C, Sicking EM, Fuss A, Jirak P, van Kuppevelt TH, Endlich K, Wetzels JF, Gröne HJ, Floege J, Moeller MJ: Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 22: 1262-1274, 2011
80. Smeets B, Angelotti ML, Rizzo P, Dijkman H, Lazzeri E, Mooren F, Ballerini L, Parente E, SagrinatiC,Mazzinghi B, Ronconi E, Becherucci F, Benigni A, Steenbergen E, Lasagni L, Remuzzi G, Wetzels J, Romagnani P: Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 20: 2593-2603, 2009
81. Smeets B, Uhlig S, Fuss A, Mooren F, Wetzels JF, Floege J, Moeller MJ: Tracing the origin of glomerular extracapillary lesions fromparietal epithelial cells. J AmSoc Nephrol 20: 2604-2615, 2009
82. Ryu M, Migliorini A, Miosge N, Gross O, Shankland S, Brinkkoetter PT, Hagmann H, Romagnani P, Liapis H, Anders HJ: Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury [published online ahead of print May 3, 2012]. J Pathol doi:10.1002/ path.4046
83. Croca SC, Rodrigues T, Isenberg DA: Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 50: 1424-1430, 2011
84. Houssiau F: Thirty years of cyclophosphamide: Assessing the evidence. Lupus 16: 212-216, 2007
85. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de RamonGarrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61-64, 2010
86. Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ: 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol 176: 2840-2847, 2010
87. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ; China Leflunomide Lupus Nephritis Study Group: Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study. Lupus 17: 638-644, 2008
88. Chan OT, Madaio MP, Shlomchik MJ: The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 169: 107-121, 1999
89. Gregersen JW, Jayne DR: B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 8: 505-514, 2012
90. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226, 2012
91. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222-233, 2010
92. Weidenbusch M, Römmele C, Schröttle A, Anders HJ: Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28: 106-111, 2013
93. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, KimHY, LeónMG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-731, 2011
94. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups: Effects of belimumab, a B lymphocyte stimulatorspecific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis 71: 1833-1838, 2012
95. Mok CC: Abatacept for systemic lupus erythematosus: The outlook. Expert Opin Biol Ther 12: 1559-1561, 2012
96. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P: The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 3077-3087, 2010
97. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A: Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7: 170-178, 2011
98. Ichikawa HT, Conley T,Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH: Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64: 493-503, 2012
99. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C,Winkler TH, Kalden JR, Manz RA, Voll RE: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748-755, 2008
100. Anders HJ: Pseudoviral immunity-a novel concept for lupus. Trends Mol Med 15: 553-561, 2009
101. Barrat FJ, Coffman RL: Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 223: 271-283, 2008
102. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C,Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM; American College of Rheumatology: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64: 797-808, 2012
103. Clowse ME, Magder L, Witter F, Petri M: Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54: 3640-3647, 2006
104. Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM; Lumina Study Group: Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61: 830-839, 2009
105. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL: Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 37: 3582-3586, 2007
106. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y,White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators: Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Ann Rheum Dis 70: 1905-1913, 2011
107. Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM,Kötter I, LakomekHJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T: Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland-a consensus report. Lupus 21: 386-401, 2012
108. Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S,AndersHJ: Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis andpneumonitis inMRL-Fas(lpr)mice. J Pharmacol Exp Ther 328: 371-377, 2009